These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10995011)

  • 1. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression.
    Pan L; Ohnishi K; Zhang WJ; Yoshida H; Maksumova L; Muratkhodjaev F; Shigeno K; Nakamura S; Luo JM; Hao HL; Fujisawa S; Naito K; Shinjo K; Takeshita A; Ohno R
    Leukemia; 2000 Sep; 14(9):1634-41. PubMed ID: 10995011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
    Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
    Inoue K; Sugiyama H; Ogawa H; Nakagawa M; Yamagami T; Miwa H; Kita K; Hiraoka A; Masaoka T; Nasu K
    Blood; 1994 Nov; 84(9):3071-9. PubMed ID: 7949179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
    Sugiyama H
    Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
    Inoue K; Ogawa H; Yamagami T; Soma T; Tani Y; Tatekawa T; Oji Y; Tamaki H; Kyo T; Dohy H; Hiraoka A; Masaoka T; Kishimoto T; Sugiyama H
    Blood; 1996 Sep; 88(6):2267-78. PubMed ID: 8822948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
    Rautenberg C; Lauseker M; Kaivers J; Jäger P; Fischermanns C; Pechtel S; Haas R; Kobbe G; Germing U; Schroeder T
    Eur J Haematol; 2021 Aug; 107(2):283-292. PubMed ID: 33987857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
    Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
    Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
    Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
    Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of a new inspection diagnostic method: genetic screening of cancer].
    Sugiyama H
    Rinsho Byori; 2004 May; 52(5):426-9. PubMed ID: 15206129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia.
    Patmasiriwat P; Fraizer G; Kantarjian H; Saunders GF
    Leukemia; 1999 Jun; 13(6):891-900. PubMed ID: 10360378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
    J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of WT1 mRNA by competitive NASBA in AML patients.
    Fukahori S
    Kurume Med J; 2001; 48(2):129-34. PubMed ID: 11501493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expressive changes of CD4(+)T cell subset transcription factors in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia and their clinical significances].
    Feng XM; Xu HZ; Zhang JY; Yin DM; Liu MM; Sui XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1038-42. PubMed ID: 25130824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Wilms tumor gene (WT1) expression in acute leukemia patients with special reference to the differential diagnosis between eosinophilic leukemia and idiopathic hypereosinophilic syndromes.
    Menssen HD; Schmidt A; Bartelt S; Arjomand A; Thomsen H; Leben R; Kath R; Thiel E
    Leuk Lymphoma; 2000 Jan; 36(3-4):285-94. PubMed ID: 10674900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of Wilms' tumor gene (WT1) in leukemias and its clinical implication].
    Wu X; Wang Y; Pei X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):16-9. PubMed ID: 10921096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia].
    Yang JK; Li JL; Li ZG; Li ZG; Liu PJ; Li JY; Lü HR; Deng Q; Lin XM; Cao JN
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Sep; 15(9):557-9. PubMed ID: 12971856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.